阿卡波糖与卡格列净单用及联用对减重术后低血糖餐后GLP-1和血糖反应的急性影响:随机交叉研究
本研究为单中心、随机、四周期交叉生理研究,纳入12例Roux-en-Y胃旁路术后发生餐后低血糖(PBH)的成人,比较安慰剂、阿卡波糖100mg、卡格列净300mg及两药联用对混合餐后总GLP-1和血糖反应的急性影响。结果显示,含阿卡波糖方案减弱餐后β细胞反应,但加用卡格列净未在预设GLP-1指标或血糖最低点上提供明确额外获益。
要点
- 含阿卡波糖方案降低餐后胰岛素、C肽及GIP峰值和AUC,但总GLP-1 AUC无组间差异。
- 卡格列净单药升高总GLP-1峰值,但所有活性治疗均未改变血糖最低点或血糖AUC。
- 血糖和β细胞反应变化未伴随总GLP-1平行降低,提示PBH急性餐后表型涉及GLP-1分泌以外的机制。
核心结论
- 含阿卡波糖方案减弱餐后β细胞反应,但加用卡格列净未在预设GLP-1结果或血糖最低点上提供明确附加获益。
研究设计与样本
- 单中心、随机、四周期交叉生理研究,纳入12例Roux-en-Y胃旁路术后PBH成人。
- 参与者接受安慰剂、阿卡波糖100mg、卡格列净300mg或联合治疗的混合餐测试。
- 共同主要终点为0-240min总GLP-1浓度-时间曲线下面积(AUC)和总GLP-1峰值浓度。
主要发现
- 安慰剂混合餐测试中,3/12例血糖<3.0mmol/L,10/12例<3.5mmol/L,10/12例报告提示低血糖的餐后症状。
- 所有活性治疗均降低血糖峰值和血糖波动,但未改变血糖最低点或血糖AUC 0-240min。
- 含阿卡波糖方案较安慰剂降低胰岛素峰值、胰岛素AUC、C肽峰值和C肽AUC。
- 总GLP-1 AUC在治疗组间无差异,但卡格列净的峰值总GLP-1高于其他治疗。
关键数值与推荐
- 血糖<3.0mmol/L(3/12例)和<3.5mmol/L(10/12例)在安慰剂混合餐中出现。
- 阿卡波糖100mg、卡格列净300mg单用及联用均降低血糖峰值和波动。
- 含阿卡波糖方案较安慰剂降低峰值GIP,联合治疗较安慰剂降低GIP AUC 0-240min。
- 联合治疗较安慰剂升高峰值胰高血糖素。
临床怎么用
- 临床可考虑阿卡波糖用于PBH患者以减弱餐后β细胞反应,但加用卡格列净可能无额外获益。
- 治疗决策应基于血糖最低点而非GLP-1水平,因活性治疗未改善血糖最低点。
局限性
- 样本量小(12例),可能限制统计效力。
- 仅评估急性单次给药效应,不反映长期治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aim To evaluate the acute effects of acarbose and canagliflozin, alone and in combination, on postprandial total GLP-1 and glycaemic responses during a mixed meal test in adults with post-bariatric hypoglycaemia (PBH). Materials and Methods This single-centre, randomised, four-period crossover physiological study included 12 adults with PBH after Roux-en-Y gastric bypass. Participants underwent meal tests after placebo, acarbose 100 mg, canagliflozin 300 mg or combination treatment. Co-primary outcomes were total GLP-1 area under the concentration–time curve (AUC) from 0 to 240 min and peak total GLP-1 concentration. Secondary outcomes included glucose, insulin, C-peptide, GIP and glucagon. Results Eleven participants completed all four visits and all 12 were analysed. During the placebo mixed meal test, 3/12 participants reached glucose < 3.0 mmol/L, while 10/12 reached < 3.5 mmol/L and 10/12 reported postprandial symptoms suggestive of hypoglycaemia. All active treatments reduced peak glucose and glucose excursion versus placebo, without changing glucose nadir or glucose AUC 0–240 min. Peak insulin, insulin AUC 0–240 min, peak C-peptide and C-peptide AUC 0–240 min were lower with both acarbose-containing regimens than with placebo. Total GLP-1 AUC 0–240 min did not differ between treatments, while peak total GLP-1 was higher with canagliflozin than with the other treatments. Peak GIP was lower with acarbose-containing regimens than with placebo, and GIP AUC 0–240 min was lower with combination treatment than with placebo. Peak glucagon was higher with combination treatment than with placebo. Conclusions Acarbose-containing regimens attenuated postprandial beta-cell responses, but adding canagliflozin did not provide clear additive benefit over acarbose alone on the prespecified GLP-1 outcomes or glucose nadir. Changes in glycaemic and beta-cell responses without a parallel reduction in total GLP-1 suggest that mechanisms beyond GLP-1 secretion contribute to the acute postprandial phenotype in PBH.
引用
- Diabetes, Obesity and Metabolism:Acute Effects of Acarbose and Canagliflozin, Alone and in Combination, on Postprandial GLP‐1 and Glycaemic Responses in Post‐Bariatric Hypoglycaemia: A Randomised Crossover Study
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。